LEXINGTON, Mass., May 17, 2022 /PRNewswire/ -- LogicBio
Therapeutics, Inc. (Nasdaq: LOGC), a clinical-stage genetic
medicine company, today announced that president and chief
executive officer, Frederic Chereau, will present a company
overview at the H.C. Wainwright Global Investment
Conference being held May 23-26, 2022. The pre-recorded
presentation will be available for on-demand viewing beginning
at 7:00 a.m. ET on Tuesday, May 24, 2022.
A webcast of the presentation will be made available on the
Investors section of the company's website
at https://investor.logicbio.com/. The webcast replay will be
available for approximately 30 days.
About LogicBio® Therapeutics
LogicBio® Therapeutics is a clinical-stage
genetic medicine company pioneering genome editing and gene
delivery platforms to address rare and serious diseases from
infancy through adulthood. The company's genome editing platform,
GeneRide®, is a new approach to precise gene insertion
harnessing a cell's natural DNA repair process potentially leading
to durable therapeutic protein expression levels. The company's
gene delivery platform, sAAVy™, is an adeno-associated virus (AAV)
capsid engineering platform designed to optimize gene delivery for
treatments in a broad range of indications and tissues. The
company's proprietary system, mAAVRx™, aims to overcome some of the
current limitations of AAV manufacturing by optimizing the
transfection process to improve yields and product quality. The
company is based in Lexington, MA. For more information,
visit www.logicbio.com, which does not form a part of
this release.
Investor Contacts:
Stephen Jasper
Gilmartin Group
858-525-2047
stephen@gilmartinir.com
Media Contacts:
Adam Daley
Berry & Company Public Relations
W:212-253-8881
C: 614-580-2048
adaley@berrypr.com
View original
content:https://www.prnewswire.com/news-releases/logicbio-therapeutics-to-present-at-hc-wainwright-global-investment-conference-301548856.html
SOURCE LogicBio Therapeutics, Inc.
